Home » Articles posted by Multichannel Admin (Page 86)
Author Archives: Multichannel Admin
Blencowe Resources #BRES – Result of General Meeting
Blencowe Resources Plc (LSE: BRES) is pleased to announce that at the Company’s General Meeting held earlier today, all resolutions were duly passed . Subject to the publication of a simplified prospectus that is currently being approved by the FCA, the passing of these resolutions gives the directors the authority to issue shares in the capital of the Company in respect of the Fundraise described in the Company’s RNS published on 12 November 2021.
Blencowe Resources #BRES – Webinar Call
Blencowe Resources (BRES:LON), the graphite explorer developing the Orom-Cross jumbo flake graphite project in Uganda, is pleased to announce that it will host a shareholder conference call and Q&A via Zoom conferencing on Monday 13 December 2021 at 12:00 noon UK time (8:00 p.m. WST time).
The call will be hosted by Blencowe’s CEO Mike Ralston who will update on the Company’s recently announced Preliminary Economic Assessment as well as discussing Blencowe’s 2022 work programme.
Interested investors are invited to register using the following link:
https://us02web.zoom.us/webinar/register/WN_0QMoNsT3TpmS1B3SouwqeA
Shareholders who wish to do so are invited to submit questions via email to info@blencoweresourcesplc.com
The most recent copy of the Company’s corporate presentation can be found at the following link:
https://blencoweresourcesplc.com/presentation/
Please note that until the Q&A session has begun that all participants will initially be muted without audio with the exception of Company management. A recording of the call will also be made available on the Company’s website following the call.
Technology Minerals #TM1 – Recyclus and WMG Partnership
Technology Minerals Plc (LSE: TM1), the first listed UK company focused on creating a sustainable circular economy for battery metals, is pleased to announce that Recyclus Group, a 49% Technology Minerals owned company, has agreed an engineering development partnership with WMG at the University of Warwick, a leading academic group providing research, education and knowledge transfer in engineering, management, manufacturing and technology.
WMG and Recyclus have created an Engineering Doctorate (“EngD”) focused on battery recycling technologies and a transfer of current and future applications. The EngD encompasses a four-year programme supporting talented individuals at varying career stages to develop new critical skills sets in this sector and will also focus on addressing contemporary industrial and technical challenges across the battery recycling sector.
Recyclus has developed the first industrial scale process that can work across all of the key Lithium-ion (“Li-ion”) battery technologies and Recyclus and WMG will be sharing this important technology through the research programmes at WMG, working across a range of development areas.
Professor David Greenwood, WMG Director for Industrial Engagement and CEO of the WMG centre High Value Manufacturing Catapult said:
“Whilst the UK industry has been remarkable in building a world class ecosystem supporting the development of our battery manufacturing capability, we must continue to innovate to capitalise on that success.
In our September 2020 report, WMG highlighted that by 2040, UK automotive lithium-ion battery cell production alone will require 131,000 tonnes of cathodic metals. With the right infrastructure, recycling can supply 22% of this demand. This represents not only a positive environmental impact, but large savings for manufacturers that build the business case for increased battery recycling capabilities in the UK.
The Recyclus Group Investment was needed to create suitable recycling facilities in the UK, and their process allows economic recovery of a large percentage of battery material. The process will help protect the environment, secure valuable raw materials, reduce the cost of transport and support the UK with its COP26 commitments.
Our joint EngD programme will help drive the development of the skills base that will support the circular economy that we will see develop around battery materials as we accelerate the transition towards an electrified future”
Alex Stanbury, Chief Executive Officer of Technology Minerals, said: “The Recyclus team have been working with WMG for nearly two years now, both sharing our respective expertise as we have been developing our proprietary processes across the five battery chemistries, and learning from WMG’s world-class research programmes. These are critical to achieving a leadership position for the UK, particularly developing proprietary technology for the processing of black mass into the key metals that can go back into the UK battery gigafactories supply chain and therefore significantly reduce the supply-side pressures.
There is a clear demand building as a result of the quantum shift to transport electrification, and that is now extending into key UK sectors, including energy storage, freight and aerospace. Working with WMG we will remain at the forefront of our sector, focused on extracting raw materials required for lithium-ion batteries, whilst solving the ecological issue of spent Li-ion batteries, by recycling them for re-use by battery manufacturers.”
With the shortage forecast for key battery minerals in the near-immediate future, there is a concern that the road to the rollout of more electric vehicles will be congested. According to the Copper Development Association (CDA), the average copper content of an ICE vehicle is around 23kg, and this will increase to 60kg for plug-in hybrid electric vehicles and to 83kg for pure EVs. Also, full electric buses can use between 224kg to 369kg of copper. According to a report released in February 2021 by the World Bureau of Metals Statistics ((WBMS)), the global copper market had a supply shortage of 1.391 million tons from January to December 2020, up from 383000 tons for the whole of 2019.
According to an article published in Nature (Future Material Demand for Automotive Lithium-based Batteries, 9 Dec 2020), the increased demand between 2020-2050 for EVs will require a drastic expansion of lithium, cobalt, and nickel supply chains and likely additional resource discovery. The Directors believe that recycling of battery materials could play an important role in reducing the pressures on supply.
Enquiries
|
Technology Minerals Limited |
|
|
Robin Brundle, Executive Chairman Alexander Stanbury, Chief Executive Officer |
+44 20 7618 9100
|
|
Alfred Henry Corporate Finance Limited |
|
|
Nick Michaels |
+44 203 772 0021 |
|
Arden Partners Plc |
|
|
Ruari McGirr |
+44 207 614 5900 |
|
Luther Pendragon |
|
|
Harry Chathli, Alexis Gore, John Bick |
+44 20 7618 9100 |
Poolbeg Pharma #POLB – agrees option agreement with UCD
#POLB featured in the Irish Times following the recently announced Option Agreement to licence #MelioVac with University College Dublin
- Potential to generate significant returns for investors
- Contributing to the global response to the threat of infectious diseases
https://www.irishtimes.com/business/health-pharma/poolbeg-pharma-agrees-option-agreement-with-ucd-1.4747770
Power Metal Resources #POW – Business Update – Red Rock Resources Australasia
Power Metal Resources PLC (LON:POW) the London listed exploration company seeking large-scale metal discoveries across its global project portfolio, announces a business update by Red Rock Resources Australasia Pty Ltd (“RRAL”).
Paul Johnson, Chief Executive Officer of Power Metal Resources plc commented:
“Exploration on our licences within the Victoria Goldfields has been successful with recent soil sampling highlighting multiple high-priority gold targets across granted licences. Certain of these targets are now at the drill-ready stage and will be the subject of the planned upcoming drill programmes, showing great progression from RRAL’s ground exploration to date.
We believe there is potential for major gold discoveries in the granted licences we hold, something which is not surprising given the geological attractiveness of the region, and multiple large-scale discoveries made and gold mines built in the state of Victoria. Therefore the launch of inaugural diamond drilling is an important step forward and we will be eager to see what this drilling delivers.”
HIGHLIGHTS:
Holding Transfer to Planned London Listing Company
Power Metal previously held a direct 49.9% interest in RRAL which has a 100% interest in the various licences held within the state of Victoria and Western Australia, further details of which are provided below.
A new UK plc has been formed, New Ballarat Gold Corporation PLC (“New Ballarat” or “NBGC”), which is the vehicle for the planned London listing. New Ballarat now holds a 100% interest in RRAL.
The original shareholders of RRAL have transferred their holdings up to the vehicle New Ballarat in preparation for the planned listing. As a result, Power Metal now holds 49.9% of New Ballarat, and Red Rock Resources plc (“RRRplc”) holds the remaining 50.1% interest.
Grant of New Exploration Licence
Exploration licence application EL007328 (164km2) was granted on November 26, 2021. Following this grant, a total of 8 licences have now been granted covering a total area of 1,012 km2.
Soil Sampling Update – New Anomalies Identified
A total of 1091 soil samples have now been tested by Portable X-ray Fluorescence (“pXRF”) from the ongoing soil sampling programme.
The interim results have identified several new anomalies as well as confirming the regional correlation of arsenic anomalism with historic gold workings and known gold-bearing structures. Highlights include:
o Buninyong (EL7271): Exciting new 1 km long north-south oriented arsenic anomaly identified which is coincident with a line of gold mineralisation extending north of Mt. Buninyong. Regional structural analysis of this new anomaly reaffirms the concept that the Scotsburn workings (which extend south-southeast of Buninyong down to O’Laughlins) is the continuation of the main Ballarat East line currently being mined underground at the Ballarat Mine (owned by Shen Yao Holdings). Additional infill soil sampling is planned within the area of the newly defined anomaly.
o Pitfield (EL7301): Strong anomalism identified surrounding known gold mineralisation at Mt. Bute. Additionally, strong arsenic anomalism identified near the west margin of the tenement in an area previously not explored. Significantly, this new anomaly is located along a roughly north-south oriented line connecting up with Mt. Bute mineralisation located over 6km away to the north, suggesting that mineralisaiton may continue in a broad north-south orientation throughout the tenement. This new area is presumed to be in part overlain by recent volcanic rocks and this may be the first indication that the pXRF sampling technique may assist in exploring for mineralisation under cover at Pitfield.
o Dereel (EL7327): Soil sampling results highlight an anomalism along the southern extension of the Golden Reefs/DeReel mine (subject to final access agreements, drilling down dip and along strike of these historic mines is planned early in 2022). Additionally, two other anomalies were identified on the tenement including a strong anomaly located in the northwest where there is no known historical information, as well as a strong response in the far southwest lines which appears to be related to the Long Thought Of mine workings (inferred southern extension of Berringa gold fields and remains largely untested). Further infill soil sampling planned over the various anomalies identified.
Further information in respect of the soil sampling programme, findings and related maps is available in today’s announcement released by Power Metal partner, RRRplc through the following link:
https://www.rrrplc.com/investors/regulatory-news/
Diamond Drilling Campaigns
Final preparations underway for multiple near-term diamond drilling campaigns including:
o Programme south of Buninyong at O’Loughlins targeting a 1km structure planned for December 2021;
o Programme at Pitfield planned for early 2022, with further targets now identified for proposed February 2022 drilling.
Currently there are 8 drill pad locations at O’Loughlins and 6 at Pitfield. In theory 2-3 drill holes could be undertaken from each location in various directions. Some holes may extend to over 100 metres, but the drilling is flexible, in part dependent on the core review as each drill hole progresses. At this time the expectation is for circa 600 metres of diamond drilling at O’Loughlins and 1,400 metres at Pitfield for a total 2,000 metres of drilling. The specific location meterage is flexible and may be subject to change depending on results.
Background Information New Ballarat Gold Corporation PLC
NBGC is a privately owned joint venture company owned as to 50.1% by Red Rock and as to 49.9% by Power Metals Resources PLC (AIM:POW).
NBGC holds a strong land position of granted exploration licences totalling 1,012 sq km in the gold-rich fields of Victoria, Australia. The company has carefully assembled its portfolio of gold properties comprising a broad range from robust exploration targets to near term resource potential, all of which remain largely undeveloped by modern explorers.
With the first tenements granted only in 2021, NBGC has already advanced three promising gold prospects to the drill-ready stage, which is slated to take place Q4 2021 & Q1 2022.
Still able to actively operate in the current global pandemic, the company has exploration geologists and field crews active in the field. This is coupled with a technical team holding in-depth knowledge of Victoria’s geology including extensive underground experience gained from working in active gold mines within the area.
Granted Licences
The granted licences cover high priority areas covering 1,102 km2 where NBGC has early drill targets and in which exploration has already started.
|
Licence Number |
Project Name |
Area (km2) |
|
EL007271
|
Buninyong (renamed) |
133 |
|
EL007281
|
Blue Chip |
74 |
|
EL007285
|
Blue Ribbon |
8 |
|
EL007327 |
Dereel |
60 |
|
EL007385 |
Sardinia |
4 |
|
EL007329 |
Kilmore |
484 |
|
EL007301 |
Pitfield/Mt Bute |
85 |
|
EL007328 |
Blue Yonder (Announced today) |
164 |
|
Total |
|
c 1,012 |
Licence Applications
RRAL has applications in process for eleven other new gold exploration licence areas covering approximately 1,294km2 in the Victoria Goldfields of Australia including:
|
License Application Number |
Project Name |
Area (km2) |
|
EL007282
|
Blue Sky |
489 |
|
EL007294 |
Red Queen |
130 |
|
EL007330 |
Daylesford (renamed) |
202 |
|
EL007460 |
Kilmore West |
325 |
|
State land within EL007271
[EL007505 EL007506 EL007507]
|
|
[9 9 8] |
|
EL007540* (3 competing applications)
|
Outer Ballarat |
148 |
|
Total |
|
c 1,294 |
* Balmaine Gold Pty Ltd, Mercator Gold Australia Pty Ltd, and Loddon Gold Pty Ltd have put in competing applications the same day as RRAL for the ground covered by EL007540. The application considered to have greatest merit will eventually be given priority.
The following applications have been made in Western Australia, covering largely areas previously held by the Company at the time of its original listing. The two where there is another applicant will be subject to a ballot.
|
EL45/5859 (One competing application) |
Paterson |
227 |
|
EL45/5885 |
Pilbara/Paterson |
70 |
|
EL45/5881 (One competing application) |
Pilbara/Paterson |
33 |
The technical information relating to exploration in this report is compiled by David Holden, BSc, MBA, MEM, who is a member of the Australian Institute of Geoscientists. Mr Holden has experience in the style of mineralisation and type of deposit under consideration. Mr Holden is the Exploration Director of RRAL.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (“MAR”), and is disclosed in accordance with the Company’s obligations under Article 17 of MAR.
For further information please visit https://www.powermetalresources.com/ or contact:
|
Power Metal Resources plc |
|
|
Paul Johnson (Chief Executive Officer) |
+44 (0) 7766 465 617 |
|
|
|
|
SP Angel Corporate Finance (Nomad and Joint Broker) |
|
|
Ewan Leggat/Charlie Bouverat |
+44 (0) 20 3470 0470 |
|
|
|
|
SI Capital Limited (Joint Broker) |
|
|
Nick Emerson |
+44 (0) 1483 413 500 |
|
|
|
|
First Equity Limited (Joint Broker) |
|
|
David Cockbill/Jason Robertson |
+44 (0) 20 7330 1883 |
Alan Green talks about Versarien #VRS , Bluefield Solar Income Fund #BSIF & Coinsilium #COIN
Alan Green talks about Versarien #VRS , Bluefield Solar Income Fund #BSIF & Coinsilium #COIN
https://www.voxmarkets.co.uk/articles/alan-green-talks-about-versarien-bluefield-solar-income-fund-coinsilium-df8cab9/
#ORPH Open Orphan Plc – Positive results from Flu Human Challenge Study
Open Orphan plc (AIM: ORPH) a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, notes the announcement released from SAB Biotherapeutics (NASDAQ: SABS) (“SAB”), reporting positive results from a human challenge study testing SAB-176, its investigational therapeutic for the treatment of seasonal influenza. hVIVO, a subsidiary of Open Orphan, conducted the Phase 2a randomised, double-blinded, placebo-controlled study using its Influenza Human Challenge Study Model.
The trial evaluated the safety and treatment efficacy of SAB-176 in 60 healthy adults challenged with a pandemic influenza strain (pH1N1). Participants were intranasally inoculated with the influenza challenge virus and then randomised to receive either SAB-176 or placebo.. SAB-176 achieved statistically significant (p = 0.026) reductions in viral load. Based on partial data, statistically significant reductions in clinical signs and symptoms compared to placebo were also observed. Additionally, no serious adverse events were reported and SAB-176 appeared to be safe and well tolerated. Based on the positive results from this study, SAB plans to further evaluate SAB-176 in a Phase 2 influenza clinical trial.
Flu is caused by the influenza virus and is one of the most common infectious respiratory diseases and can lead to severe illness, and death. There are four types of seasonal influenza viruses, types A, B, C and D. Influenza A and B viruses circulate and cause seasonal epidemics of disease. According to the World Health Organisation (WHO), worldwide, these annual epidemics are estimated to result in about three to five million cases of severe illness, and about 290 000 to 650 000 respiratory deaths.
hVIVO has two decades of experience and expertise in safely conducting challenge studies across a range of respiratory and infectious disease viruses, including respiratory syncytial virus (RSV), Influenza, human Rhinovirus HRV (common cold virus), malaria, and asthma. In October 2020, this expanded to include the SARS-CoV-2 virus.
Cathal Friel, Executive Chairman of Open Orphan, said : “I am pleased that SAB has received positive results for SAB-176 from its influenza human challenge trial, conducted by hVIVO. SAB-176 met its primary endpoint and based on partial data appears to have met a key secondary endpoint. These encouraging results support proceeding to a Phase 2 clinical trial.
“Influenza affects a significant proportion of the global population every year with symptoms ranging from mild to severe, with hospitalisations and deaths occurring among high-risk groups. hVIVO has successfully been delivering Influenza human challenge trials for over two decades, and we look forward to continuing to support Big Pharma and biotechs to provide early proof-of-concept for novel vaccines and antivirals.”
Mariya Kalinova, Medical Director, hVIVO, commented: “We are delighted to see these positive results from the Phase 2a Influenza Human Challenge Study for SAB Biotherapeutics’ novel anti-influenza human immunotherapy, SAB-176. The encouraging reductions in viral load and clinical symptoms, along with the promising safety and tolerability data observed in this challenge study suggest SAB-176 may have a positive impact on individuals with influenza.
“This successful study demonstrates the way that Phase 2a challenge studies can help advance drug development and provide a value inflection point for innovative products such as SAB-176 as they move towards a full Phase 2 study. Moving forward, we expect to see an increase in the number of human challenge studies taking place across multiple infectious diseases, as interest in these disease areas continues to grow.”
For further information please contact:
|
Open Orphan plc |
+353 (0) 1 644 0007 |
||
|
Cathal Friel, Executive Chairman |
|||
|
Arden Partners plc (Nominated Adviser and Joint Broker) |
+44 (0) 20 7614 5900 |
||
|
John Llewellyn-Lloyd / Louisa Waddell |
|||
|
finnCap plc (Joint Broker) |
+44 (0) 20 7220 0500 |
||
|
Geoff Nash / James Thompson/ Richard Chambers |
|||
|
Davy (Euronext Growth Adviser and Joint Broker) |
+353 (0) 1 679 6363 |
||
|
Anthony Farrell |
|||
|
Walbrook PR (Financial PR & IR) Paul McManus/ Sam Allen / Louis Ashe-Jepson |
+44 (0)20 7933 8780 or openorphan@walbrookpr.com +44 (0)7980 541 893 / +44 (0) 7502 558 258 / +44 (0) 7747 515393 |
||
#POLB Poolbeg Pharma – Poolbeg signs option for new vaccine candidate
6 December 2021 – Poolbeg Pharma (AIM: POLB), ‘Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed an Option Agreement to licence MelioVac, a vaccine for melioidosis, with University College Dublin (‘UCD’) and its inventor, Associate Professor Siobhán McClean , through NovaUCD, the university’s knowledge transfer office.
The Company will continue its due diligence on MelioVac, a preclinical asset and recipient of a Wellcome Trust Award to aid its development, as well as 5 of other potential vaccine candidates discovered by Associate Professor McClean and her team, for the duration of the Option Agreement, prior to signing a ‘Licence Agreement’.
Dr McClean is Associate Professor and Head of Biochemistry at the UCD School of Biomolecular and Biomedical Science. Dr McClean completed her BSc in Biochemistry in UCD and received her PhD from Imperial College London. Her research focuses on lung infections which led her to develop a platform technology to identify proteins that bacteria use to attach to human cells. These proteins have proved to be excellent vaccine candidates. Dr McClean completed some of the original research to identify the antigens associated with the Melioidosis Vaccine at TU Dublin.
Poolbeg Pharma has identified melioidosis as an infectious disease of interest due to its rising incidence around the world and because there is currently no approved vaccine available. Concerns are growing about global warming contributing to the spread of the disease to traditionally non-tropical areas.
Melioidosis, also known as Whitmore’s disease, is an infectious disease caused by the bacterium Burkholderia pseudomallei, commonly found in the soil and surface groundwater of many tropical and subtropical regions, with diverse clinical presentations including pneumonia and severe sepsis with multiple organ abscesses. Incidence of the disease is widespread in South-East Asia, Northern Australia and India, with climate change having a substantial impact on the spread of the disease to new areas such as Brazil. There are an estimated 165,000 cases of melioidosis each year, of which as many as 89,000 (54%) are estimated to be fatal.
Other potential vaccine candidates that the Company is evaluating include those for Klebsiella pneumoniae,Escherichia coli (O157), Burkholderia cepacia complex, Pseudomonas aeruginosa and Acinetobacter baumannii.
Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said:
“Melioidosis offers Poolbeg an opportunity to expand our portfolio of infectious disease assets, as promised at IPO. This is a disease which presents a dangerous and underappreciated threat to human health which currently has no approved vaccine and a very high mortality rate. If we can take MelioVac through clinical development to Phase II ready, it has the potential to generate significant returns for investors in the short-term while contributing to the global response to the threat of infectious diseases with an unmet medical need. We are excited by the potential of the MelioVac opportunity along with the other vaccine candidates in the UCD portfolio.”
Siobhán McClean, Associate Professor at the UCD School of Biomolecular and Biomedical Science and inventor of MelioVac , said:
“We are passionate about developing a vaccine against Melioidosis. Poolbeg Pharma is a great potential partner to work with, bringing its experience of vaccine development and industry connections to our innovative science. On the basis that a license is taken, it would be a great to see the development of MelioVac and other candidates, and contribute significantly to the world’s renewed fight against infectious diseases.”
– Ends –
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 (as implemented into English law) (“MAR”). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
Enquiries
|
Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, CFO
|
+353 (0) 1 644 0007 |
|
finnCap Ltd (Nominated Adviser & Joint Broker) Geoff Nash, James Thompson, Charlie Beeson, Richard Chambers, Sunila de Silva (ECM)
|
+44 (0) 20 7220 0500 |
|
Arden Partners PLC (Joint Broker) John Lewellyn-Lloyd, Louisa Waddell
|
+44 (0) 207 614 5900 |
|
J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist
|
+353 (0) 1 679 6363 |
|
Instinctif Partners Melanie Toyne Sewell, Rozi Morris, Tim Field |
+44 (0) 20 7457 2020 poolbeg@instinctif.com |
#TM1 Technology Minerals – UK EV battery recycling hots up with Technology Minerals
15 years from now, it is estimated there will be some 250,000 tones of spent EV battery packs, and they all have to go somewhere.
Thankfully, EV batteries aren’t nuclear waste; we can recycle them to extract raw materials and reuse those materials to make more batteries.
Like the plastic trays and milk bottles you throw in the bin, used EV batteries are recycled to separate the useful minerals from the chaff. This not only reduces our dependency on virgin materials but slashes carbon emissions in the supply chain.
The recycling process shreds the EV batteries, creating a black mass, which consists of high amounts of lithium, manganese, cobalt, and nickel metals. Those metals are refined further to create a fresh supply of rare and uncommon metals.
Battery recycling for electric vehicles includes both the main battery pack and the 12V battery, which can be lead-acid or lithium-ion.
The ultimate goal is to create a closed-loop manufacturing process. In November, Northvolt announced the world’s first 100% recycled EV battery.
UK EV battery recycling
In the UK, battery recycling facilities are relatively common, but facilities that recycle EV batteries are not. You see, EV batteries are enormous, and they have a different chemical composition to the batteries in your smartphone, requiring different recycling and refinement processes. The process is expensive and difficult.
Technology Minerals PLC, a British company, aims to change this as the UK’s first listed company to create a circular economy in the battery metals sector.
They aim to achieve this with proprietary recycling technology and a partnership agreement with a leading hazardous waste company, working closely with them to design and develop recycling facilities that can recycle EV batteries at scale.
The deal will see Recyclus Group, a 49% Technology Minerals owned company, partner with hazardous waste management and service delivery provider Slicker Recycling. The partnership will boost recycling output for lithium-ion batteries with a high level of refinement, preserving the quality of the extracted metals with great efficiency.
“There is a clear demand building as a result of this quantum shift to electrification,” says Alex Stanbury, CEO of Technology Minerals.
“We are focused on extracting raw materials required for lithium-ion batteries, whilst solving the ecological issue of spent Li-ion batteries, by recycling them for re-use by battery manufacturers.”
The demand for electrification is only going to increase, and we have to come to terms with the battery waste this will create.
The move by Technology Minerals is the first of its kind in the UK and a welcome step in the right direction for EV battery recycling.
Power Metal Resources #POW – Exercise of Warrants
Power Metal Resources plc (LON:POW) the London listed exploration company seeking large-scale metal discoveries across its global project portfolio announces it has received a notice to exercise warrants over 8,750,000 new ordinary shares of 0.1 pence each in the Company (“Warrant Shares”) raising an additional £61,250 for the Company.
The Warrant Shares are being issued pursuant to the exercise of 8,750,000 warrants at an exercise price of 0.7 pence per ordinary share of 0.1 pence each in the Company (“Ordinary Share).
ADMISSION AND TOTAL VOTING RIGHTS
Application will be made for the 8,750,000 Warrant Shares to be admitted to trading on AIM which is expected to occur on or around 9 December 2021 (“Admission”). The Warrant Shares will rank pari passu in all respects with the ordinary shares of the Company currently traded on AIM.
Following Admission, the Company’s issued share capital will comprise 1,358,339,987 ordinary shares of 0.1p each. This number will represent the total voting rights in the Company and may be used by shareholders as the denominator for the calculation by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority’s Disclosure and Transparency Rules.